OBJECTIVES We assessed the knowledge and awareness of cervical cancer, HPV and HPV vaccine, and willingness and acceptability to vaccinate in sub-Saharan African (SSA) countries. We further identified countries that fulfill the two GAVI Alliance eligibility criteria to support nationwide HPV vaccination. METHODS We conducted a systematic review of peer-reviewed studies on the knowledge and aw...

Since mid-2006, the Advisory Committee on Immunization Practices (ACIP) has recommended routine vaccination of adolescent girls at ages 11 or 12 years with 3 doses of human papillomavirus (HPV) vaccine. Two HPV vaccines are currently available in the United States. Both the quadrivalent (HPV4) and bivalent (HPV2) vaccines protect against HPV types 16 and 18, which cause 70% of cervical cancers ...

Although immunization with two highly efficacious human papillo-mavirus (HPV) vaccines holds great promise for reducing the global burden of HPV-related cancers, the barriers to achieving this goal remain substantial. The cost of HPV vaccination still represents an important obstacle to implementation in many countries but there are several challenges beyond the high cost (1). It has proven dif...

OBJECTIVES To investigate adolescent vaccination in New York City, we assessed tetanus, diphtheria, and acellular pertussis (Tdap), meningococcal conjugate (MCV4), and human papillomavirus (HPV) vaccine uptake, vaccine co-administration, and catch-up coverage over time. METHODS We analyzed data from the Citywide Immunization Registry, a population-based immunization information system, to mea...

INTRODUCTION Since 2007, HPV vaccine has been available to low and middle income countries (LAMIC) for small-scale 'demonstration projects', or national programmes. We analysed coverage achieved in HPV vaccine demonstration projects and national programmes that had completed at least 6 months of implementation between January 2007-2016. METHODS A mapping exercise identified 45 LAMICs with HPV...

This paper describes a possible multifaceted approach to human papillomavirus (HPV) related surveillance in Australia following implementation of a national HPV vaccination program. We describe eight main components: monitoring of vaccine coverage, vaccine safety, type-specific HPV infection surveillance, cervical cytology (Pap screening) coverage and screen detected lesion prevalence, cervical...

BACKGROUND We tested the hypothesis that states with higher rates of cancers associated with human papillomavirus (HPV) would have lower HPV vaccine coverage. METHODS We gathered state-level data on HPV-related cancer rates and HPV vaccine initiation coverage for girls and boys, separately, and HPV vaccine follow-through (i.e., receipt of 3 doses among those initiating the series) for girls o...

BACKGROUND We compared vaccine coverage achieved by 2 different delivery strategies for the quadrivalent human papillomavirus (HPV) vaccine in Tanzanian schoolgirls. METHODS In a cluster-randomized trial of HPV vaccination conducted in Tanzania, 134 primary schools were randomly assigned to class-based (girls enrolled in primary school grade [class] 6) or age-based (girls born in 1998; 67 sch...

BACKGROUND Increasingly, countries have introduced female vaccination against human papillomavirus (HPV), causally linked to several cancers and genital warts, but few have recommended vaccination of boys. Declining vaccine prices and strong evidence of vaccine impact on reducing HPV-related conditions in both women and men prompt countries to reevaluate whether HPV vaccination of boys is warra...

The nation’s cancer status report in 2013 highlighted that cancers attributable to human papilloma virus (HPV) increased in the past decade, particularly cancers in the oropharynx and anus.1 HPV vaccine is crucial in reducing the burden of HPV-associated cancers, by protecting against HPV infections that cause cervical, vulvar, vaginal, anal and oropharyngeal cancers.2,3 Non-cancerous lesions, ...